Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Industry News

NeuMoDx launches molecular systems at AMP

Nov. 12, 2018—NeuMoDx Molecular announced the U.S. launch of its FDA 510(k)-cleared NeuMoDx 288 Molecular System and its FDA-listed NeuMoDx 96 Molecular System at the Association for Molecular Pathology annual meeting in San Antonio. The fully automated systems integrate the molecular diagnostic process, from extraction to detection, with the first result available in approximately one hour. The analyzers offer operators the ability to load up to 288 and 96 patient samples, respectively, in a continuous, random-access workflow, resulting in on-demand,

MediPath selects NovoPath as its AP LIS

Nov. 8, 2018—NovoPath announced that its anatomic pathology software platform has been selected by MediPath as its laboratory information system. “During the thorough selection process, MediPath had an opportunity to survey the capabilities of several vendors,” Sandra Aponte, MD, medical director and lead pathologist for MediPath, said in a statement. “NovoPath’s solution best aligned with MediPath’s needs and offered the most robust and flexible capabilities at a competitive price. We felt it was the best choice to help position us

Illumina to buy PacBio for $1.2 billion

Nov. 7, 2018—Illumina announced it will acquire Pacific Biosciences for approximately $1.2 billion. With this acquisition, Illumina will be positioned to provide integrated workflows and novel innovations that bring together both Illumina’s short-read sequencing platforms with PacBio’s long-read sequencing capabilities to help researchers advance their discoveries faster and clinicians offer new tests economically. “PacBio’s unmatched accuracy mirrors that of Illumina’s in short-read sequencing. Combining the two technologies positions us to reach more applications, accelerate the pace of genomic discovery and

FDA clears Ortho’s Vitros XT 7600 Integrated System

Nov. 5, 2018—Ortho Clinical Diagnostics received FDA clearance for its Vitros XT 7600 Integrated System. The Vitros XT 7600 uses the company’s Digital Chemistry technology, which combines microslide technology, digital imaging, and dry slide technology. “It’s an exciting time for clinical labs, and today’s clearance of Ortho’s Vitros XT 7600 System represents a fundamental improvement in the way labs can operate, now and in the future,” Jennifer Paine, Ortho’s chief product portfolio officer, said in a press release. “Vitros XT

Illumina launches TruSight Oncology 500

Nov. 1, 2018—Illumina  launched its TruSight Oncology 500, a comprehensive next-generation sequencing assay. TSO 500 uses DNA and RNA to identify multiple variant types, including small nucleotide variants, indels, splice variants, fusions, and tumor mutational burden and microsatellite instability from the same formalin-fixed, paraffin-embedded tumor sample. The panel contains 1.94 Mb of genomic content to measure TMB and offers sophisticated variant calling and germline filtering algorithms for enhanced accuracy. “The importance of tumor mutational burden as a biomarker to predict immune

Abbott next-gen influenza A & B, strep A assays

Oct. 29, 2018—Abbott announced FDA clearance and CLIA waiver of its next-generation Influenza A & B 2 and Strep A 2 molecular assays for point-of-care testing. The Influenza A & B 2 assay detects and differentiates influenza A and B virus in 13 minutes or less, with early call out of positive results in as few as five minutes. The Strep A 2 provides molecular detection of group A Streptococcus bacterial nucleic in six minutes or less, with call out of

NeoGenomics to acquire Genoptix

Oct. 26, 2018—NeoGenomics has entered into a definitive agreement to acquire Genoptix for $125 million in cash and 1 million shares of NeoGenomics common stock. “The acquisition of Genoptix enhances NeoGenomics’ leadership in the oncology test market, significantly expanding our coverage of oncology practices, increasing our customer reach, and leaving us better positioned for growth,” Douglas M. VanOort, NeoGenomics’ chairman and CEO, said in a press release. “With what we believe to be the most comprehensive oncology test menu in

Xifin rolls out RPM 10

Oct. 24, 2018—Xifin unveiled its Xifin Revenue Performance Management 10 to help diagnostic providers improve revenue, performance, and client and patient engagement. Xifin RPM 10 is a machine learning-enabled diagnostic revenue cycle management system that delivers an FASB-, GAAP-, and SOX-compliant and GL-ready financial package. Its new business intelligence capabilities include subject-oriented and aggregated data, data visualization, and analytics to help labs better understand and make use of their data and financial information. The system features a patient responsibility estimator and

BRACAnalysis CDx approved as Talzena companion dx

Oct. 22, 2018—Myriad Genetics announced that the FDA has approved its BRACAnalysis CDx to identify patients with HER2-negative metastatic breast cancer who have a germline BRCA mutation and are eligible for treatment with Pfizer’s PARP inhibitor, Talzena (talazoparib). Talzena is indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. “We congratulate Pfizer on obtaining FDA approval of Talzena for certain patients living with metastatic breast cancer, and we

Beckman Coulter joins forces with Johns Hopkins

Oct. 18, 2018—Beckman Coulter Diagnostics is collaborating with Johns Hopkins Medicine to explore co-innovation initiatives with the goal of developing and commercializing novel solutions that address challenges in health care.

MARKETPLACE

TRENDING